Dittmann S, Roggendorf M, Dürkop J, Wiese M, Lorbeer B, Deinhardt F
Central Institute of Hygiene, Microbiology, and Epidemiologie, Berlin, Federal Republic of Germany.
J Hepatol. 1991 Nov;13(3):323-7. doi: 10.1016/0168-8278(91)90076-n.
The occurrence of antibodies to hepatitis C virus (HCV) was investigated in 81 patients who developed hepatitis non-A, non-B (HNANB) after parenteral administration of contaminated immunoglobulin to prevent Rh sensitization. Sera from 74 of the 81 patients (89.9%) were anti-HCV positive at either 6-12 months or 9-10 years after administration of immunoglobulin. Sera were not available from any patients at either of the times: however, 52 of 56 sera (92.9%) were anti-HCV positive 6-12 months after use of immunoglobulin, and anti-HCV was present in 45 of 65 sera (69.2%) 9-10 years after immunoglobulin treatment. Of the latter, only two of 13 (15.4%) sera from patients who recovered from hepatitis were anti-HCV positive, whereas 43 of 52 patients (82.7%) with chronic disease were anti-HCV positive. The ELISA using a recombinant antigen was found a good detector as marker for a HCV infection because 90% of patients infected by a common source became anti-HCV positive. However, 10 years after infection most patients who did not develop chronic disease no longer had detectable antibodies.
对81例因注射受污染的免疫球蛋白预防Rh致敏后发生非甲非乙型肝炎(HNANB)的患者进行了丙型肝炎病毒(HCV)抗体出现情况的调查。在注射免疫球蛋白后的6至12个月或9至10年,81例患者中有74例(89.9%)的血清抗HCV呈阳性。在这两个时间点均未获取到任何患者的血清样本:然而,在使用免疫球蛋白后的6至12个月,56份血清中有52份(92.9%)抗HCV呈阳性,在免疫球蛋白治疗后的9至10年,65份血清中有45份(69.2%)存在抗HCV。在后者中,从肝炎中康复的患者的13份血清中只有2份(15.4%)抗HCV呈阳性,而52例慢性病患者中有43例(82.7%)抗HCV呈阳性。发现使用重组抗原的ELISA是检测HCV感染的良好标志物,因为90%由共同来源感染的患者抗HCV呈阳性。然而,感染10年后,大多数未发展为慢性病的患者不再有可检测到的抗体。